Spectrum Pharmaceuticals, Inc. (SPPI) Reports 45% Sales Growth In The Second Quarter, Launches Fifth Product And Moves Closer To A Decision On A Potential Blockbuster
8/8/2014 9:58:19 AM
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended June 30, 2014. “The first half of the year has delivered significant growth and we are excited about the Company’s sales trajectory,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “With the approval and launch of our fifth drug, Beleodaq, we are now a leader in lymphoma treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by